Thrombocytosis-associated ticagrelor non-responder status after ECMO-supported primary PCI in STEMI. [PDF]
Strohhofer C, Alber H, Dörler J.
europepmc +1 more source
Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature. [PDF]
Dello Russo C +5 more
europepmc +1 more source
Safety and efficacy of flow diversion for blood blister aneurysms: A comprehensive systematic review and meta-analysis. [PDF]
Maroufi SF +3 more
europepmc +1 more source
Ticagrelor Resistance Causing Acute In-Stent Thrombosis: Successful Management With Prasugrel and Balloon Angioplasty. [PDF]
Jia K +4 more
europepmc +1 more source
Efficacy and safety of off-label low-dose compared with standard-dose antiplatelet agents in patients with coronary heart disease: a meta-analysis. [PDF]
Zheng L +11 more
europepmc +1 more source
Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials. [PDF]
Navarese EP +12 more
europepmc +1 more source
Retrospective observational analysis of prasugrel dosage afterpercutaneous coronary intervention using the Clinical Deep DataAccumulation System database. [PDF]
Hiroi Y +24 more
europepmc +1 more source
Safety and Efficacy Comparison of Ticagrelor versus Other P2Y12 Inhibitors in Combination with Oral Anticoagulants as a Part of DAPT/SAPT in Patients with Concomitant Atrial Fibrillation and Coronary Artery Disease: A Meta-Analysis. [PDF]
Li Y, Gong J, Liu N.
europepmc +1 more source
Management of Bleeding Disorder During Dual Antiplatelet Therapy. [PDF]
Madaudo C, Galassi AR, Vadalà G.
europepmc +1 more source
Early discontinuation of acetylsalicylic acid after angioplasty in acute coronary syndromes: the NEO-MINDSET and TARGET-FIRST studies. [PDF]
Di Leo G, Nastasi D, Capodanno D.
europepmc +1 more source

